



Please Join Us for a Non-CME Industry Satellite Symposium (ISS11), Financially Supported by Karuna Therapeutics During the 36th Annual ECNP Congress

FORGING A NEW PATH:

# Targeting Muscarinic Receptor Circuits in Schizophrenia

Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on an evolving class of investigational therapeutics that have shown promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.

**Monday, October 9 | 8:30AM-10:00AM**

Centre Convencions Internacional de Barcelona (CCIB) | Room 113, Level 1

*Breakfast will be available*



CHAIR

**Robert A. McCutcheon,**  
PhD, MBBS

United Kingdom



**Manpreet Kaur Singh,**  
MD, MS, DFAACAP

United States



**Carol A. Tamminga, MD**

United States

For more information about Karuna Therapeutics,  
please visit [www.karunatx.com](http://www.karunatx.com)



[www.karunatx.com](http://www.karunatx.com)

©2023 Karuna Therapeutics™. All Rights Reserved. MRC-0020 6/23

Meal is provided by Karuna Therapeutics. Karuna may publicly disclose attendees' information and the value of any food, drink, educational item, or any other item of value provided to attendees in connection with this program in order to comply with regulatory and legal requirements.

